Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumors

International Journal of Gynecological Pathology

Volumn 18, Issue 4, 1999, Pages 344-350

  Tan, Yi ^a   Sinniah, Raja ^a   Bay, Boon Huat ^a   Singh, Gurmit ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Metallothionein expression; Nuclear size; Ovarian mucinous tumors; Prognostic indices

Indexed keywords

METALLOTHIONEIN;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYSTADENOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OVARY TUMOR; PRIORITY JOURNAL; TUMOR RECURRENCE;

EID: 0032879167     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199910000-00009     Document Type: Article

References (22)

1. Russell R. Surface epithelial-stromal tumors of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag, 1994:705-82.
2. Hart WR, Norris HJ. Borderline and malignant mucinous tumor of ovary. Cancer 1973;31:1031-45.
3. Colgan TJ, Norris HJ. Ovarian epithelial tumors of low malignant potential: a review. Int J Gynecol Pathol 1983;1:367-82.
4. Silva EG, Kurman RJ, Russell P, Scully RE. Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996;15: 281-302.
5. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 1998;22:1449-62.
6. Kagi GHR. Overview of metallothionein. Methods Enzymol 1990; 205:613-6.
7. Hammer DH. Metallothionein. Annu Rev Biochem 1986;55:913-51.
8. Fuller CE, Elmes ME, Jasani B. Age-related changes in metallothionein, copper, copper-associated protein, and lipofuscin in human liver: a histochemical and immunohistochemical study. J Pathol 1990;161:167-72.
9. Cherian MG, Howell SB, Imura N, et al. Contemporary issues in toxicology-role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994;126:1-5.
10. Goncharova EI, Rossman TG. A role for metallothionein in spontaneous mutagenesis. Cancer Res 1994;54:5318-23.
11. Kondo Y, Woo ES, Michaska AE, Choo KHA, Lazo JS. Metallothionein null-cells have increased sensitivity to anticancer drugs. Cancer Res 1995;55:2021-3.
12. Jasani B, Edwards M, Vujanic G, et al. Infrequent overexpression of metallothionein (MT) in pediatric tumors and its possible significance [Abstract]. J Pathol 1997;181:38A.
13. Jasani B, Schmid KW. Significance of metallothionein overexpression in human tumors. Histopathology 1997;31:211-4.
14. Tan Y, Sinniah R, Bay BH, Singh G. Metallothionein expression and nuclear size in benign, borderline and malignant serous ovarian tumors. J Pathol 1999 (in press).
15. Bier B, Douglas-Jones AG, Totsch M, Dokhorn-Dworniczak B, Bocker W, Jasani B, Schmid KW. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant lesions. Breast Cancer Res Treat 1994;30: 213-21.
16. Schmid KW, Ellis IO, Gee JM, et al. Presence and possible significance of immunocytochemically demonstrable metallothionein overexpression in primary invasive ductal carcinoma of the breast. Virchows Arch A 1993;422:153-9.
17. Bakka A, Johnsen ABS, Endersen I, Rugstad HE. Radioresistance in cells with high content of metallothionein. Experientia 1982; 38:381-3.
18. Bay BH, Sit KH, Paramanantham R, Chan YG. Hydroxyl free radicals generated by vanadyl [IV] induce cell blebbing in mitotic Chang liver cells. BioMetals 1997;10:119-22.
19. Jasani B, Elmes ME. Immunohistochemical detection of metallothionein. Methods Enzymol 1991;205:95-107.
20. Niclini C. Nuclear morphometry, quinternary chromatin structure and cell growth. J Submicros Cytol 1980;12:475-505.
21. Komitowski D, Skonka I, Schmitt B, Muto S. Quantitative description of nuclear morphology in assessing resistance of sarcome 180 to Adriamycin. Cytometry 1987;8:625-31.
22. Miller BE, Lavia LA, Horbelt DV. The prognostic value of image analysis in ovarian cancer. Cancer 1991;5:1318-21.